Role of Lymphadenectomy for Prostate Cancer: Indications and Controversies

Urologic Clinics of North America

Volumn 38, Issue 4, 2011, Pages 387-395

  La Rochelle, Jeffrey C ^a   Amling, Christopher L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Lymph node dissection; Lymphadenectomy; Prostate cancer; Staging

Indexed keywords

ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PATIENT SELECTION; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION;

BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PELVIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80955136559     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2011.07.009     Document Type: Review

References (46)

1. Hovels A.M., Heesakkers R.A., Adang E.M., et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008, 63:387-395.
2. Heesakkers R.A., Hovels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
3. Poulsen M.H., Bouchelouche K., Gerke O., et al. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010, 106:639-643.
4. Hacker A., Jeschke S., Leeb K., et al. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F] fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2006, 176:2018-2019.
5. Link R.E., Morton R.A. Indications for pelvic lymphadenectomy in prostate cancer. Urol Clin North Am 2001, 28:491-498.
6. Heidenreich A., Varga Z., von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metstasis. J Urol 2002, 167:1681-1686.
7. Mattei A., Fuechsel F.G., Bhatta Dhar N., et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008, 53:118-125.
8. Bader P., Burkhard F.C., Markwalder R., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 2003, 169:849-854.
9. Murray S.K., Breau R.H., Guha A.K., et al. Spread of prostate carcinoma to the perirectal lymph node basin. Am J Surg Pathol 2004, 28:1154-1162.
10. Schumacher M.C., Burkhard F.C., Thalmann G.N., et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54:344-352.
11. Toujier K., Rabbani F., Otero J.R., et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 2007, 178:120-124.
12. Makarov D.V., Trock B.J., Humphreys E.B., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin Tables) based on cases from 2000 to 2005. Urology 2007, 69:1095-1101.
13. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003, 170:1798-1803.
14. Kawakami J., Meng M.V., Sadetsky N., et al. Changing patterns of pelvic lymphadenectomy for prostate cancerL: results from CaPSURE. J Urol 2006, 176:1382-1386.
15. Allaf M.E., Palapattu G.S., Trock B.J., et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004, 172:1840-1844.
16. Godoy G., Chong K.T., Cronin A., et al. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement. Eur Urol 2011, 60:195-201.
17. Briganti A., Chun F.K.H., Salanoia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006, 49:1019-1027.
18. Weckermann D., Goppelt M., Dorn R., et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of <10 ng/ml and biopsy Gleason score of < 6, and their infuence on PSA progression-free survival after radical prostatectomy. BJU Int 2006, 97:1173-1178.
19. Burkhard F.C., Pader P., Schneider E., et al. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol 2002, 42:84-92.
20. Schumacher M.C., Burkhard F.C., Thalmann G.N., et al. Is pelvic lymph node dissection necessary in patients with a serum PSA, 10ng/ml undergoing radical prostatectomy for prostate cancer?. Eur Urol 2006, 50:272-279.
21. Morgan T.M., Lange P.H., Porter M.P., et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009, 15:677-683.
22. Joslyn S.A., Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006, 68:121-125.
23. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005, 17:1248-1253.
24. Gofrit O.N., Zorn K.C., Steinberg G.D., et al. The Will Rogers phenomenon in urological oncology. J Urol 2008, 179:28-33.
25. Masterson T.A., Bianco F.J., Vickers A.J., et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006, 175:1320-1325.
26. Weight C.J., Reuther A.M., Gunn P.W., et al. Limited pelvic lymph node dissection does not improve survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology 2008, 71:141-145.
27. DiMarco D.S., Zincke H., Sebo T.J., et al. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005, 173:1121-1125.
28. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-479.
29. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome afetr radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178:864-871.
30. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004, 172:2252-2255.
31. Palapattu G.S., Allaf M.E., Trock B.J., et al. Prostate specifc antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term follow-up. J Urol 2004, 172:1860-1864.
32. Bigg S.W., Catalona W.J. Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology 1992, 39:309-313.
33. Kropfl D., Krause R., Hartung R., et al. Subcutaneous heparin injection in the upper arm as a method of avoiding lymphoceles after lymphadenectomies in the lower part of the body. Urol Int 1987, 42:416-423.
34. Clark T., Parekh D.J., Cookson M.S., et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003, 169:145-148.
35. Musch M., Klevecka V., Roggenbuck U., et al. Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006. J Urol 2008, 179:923-929.
36. Briganti A., Chun F.K., Salonia A., et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006, 50:1006-1013.
37. Tokuda Y., Carlino L.J., Gopalan A., et al. Prostate cancer topography and patterns pf lymph node metastasis. Am J Surg Pathol 2010, 34:1862-1867.
38. Zorn K.C., Katz M.H., Bernstein A., et al. Pelvic lymphadenectomy during robot-assisted radical prostatectomy: assessing nodal yield, perioperative outcomes, and complications. Urology 2009, 74:296-304.
39. Eifler J.B., Levinson A.W., Hyndman M.E., et al. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism during laparoscopic radical prostatectomy. J Urol 2011, 185:1661-1666.
40. Thompson I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181:956-962.
41. Da Pozza L.F., Cozzarini C., Briganti A., et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenopathy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009, 55:1003-1011.
42. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041.
43. Briganti A., Karnes J.R., Da Pazzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer-specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55:261-270.
44. American Urological Association Prostate-Specific Antigen Best Practice Statement: 2009 Update. Available at: Accessed March 3, 2011. http://auanet.org.
45. European Association of Urology 2010 Guidelines on Prostate Cancer. Available at: Accessed March 3, 2011. http://uroweb.org.
46. National Comprehensive Cancer Network Guidelines Version 1.2011 Prostate Cancer. Available at: Accessed January 3, 2011. http://nccn.org.